Shares in an ASX-listed medical technology firm backed by investors including Bill Ferris and Mark Carnegie have surged 10.5 per cent on Monday after it revealed positive clinical trial results, which clear the way for US Food and Drug Administration approval for its tiny cardiovascular device.
EBR Systems chief executive John McCutcheon says the trials are the most significant development for the company so far.
Loading...
Tess Bennett is a technology reporter with The Australian Financial Review, based in the Brisbane newsroom. She was previously the work & careers reporter. Connect with Tess on Twitter. Email Tess at tess.bennett@afr.com
